Dexcom, Inc., headquartered in San Diego, CA, is dedicated to developing innovative glucose sensing technology and products to help patients and healthcare providers better manage diabetes. The Dexcom G6™ Continuous Glucose Monitoring (CGM) System does not require fingersticks for calibration or diabetes treatment decisions* and features simple, one-touch sensor insertion. The System provides exceptional accuracy with an overall MARD of 9.0%† and features an Urgent Low Soon alert that can warn users 20 minutes in advance of severe hypoglycemia (55 mg/dL). Dexcom is the only provider of CGM systems indicated for children ages 2 years and older. Please visit www.dexcom.com.
*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.
†MARD is a statistical measure of accuracy; the lower the number, the better.
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research, collaboration and quality manufacturing we strive to make life better for people affected by diabetes and related conditions. We work to deliver breakthrough outcomes through innovative solutions—from medicines and technologies to support programs and more.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod® product platform. The Omnipod® Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod® technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod® Insulin Management System to bring simplicity and freedom to their lives. For more information, visit www.myomnipod.com.
In 1923, the founders of Novo Nordisk began a journey to change diabetes. Today, we are thousands of employees across the world with the passion, the skills and the commitment to continue this journey to prevent, treat and ultimately cure diabetes. Novo Nordisk is proud to once again be a Platinum Level Sponsor of the Friends for Life conference, supporting the Family and Friends Banquet and Sports Central. Please come see us at the exhibition to learn more about our type 1 support program, our new camp program and be among the first to learn about the first and only durable insulin pen with 0.5 unit doing and memory function – NovoPen Echo®. To learn more about Novo Nordisk and our support to the type 1 diabetes community visit us at www.novonordisk-us.com.
Friends of CWD
Beta Bionics is a public benefit corporation and certified B corp. committed to commercializing the iLet® bionic pancreas. We’re a people-focused company, here to serve the wider diabetes community. We want to make a difference and aim to improve the lives of people living with diabetes and hope to reduce the data and decision-making overload that PWD and their caregivers often deal with. To learn more about Beta Bionics, our team and our mission visit us at www.betabionics.com and @BetaBionics on social media.
JDRF is the leading global organization focused on type 1 diabetes (T1D) research. Driven by passionate, grassroots volunteers connected to children, adolescents, and adults with this disease, JDRF is now the largest charitable supporter of T1D research. The goal of JDRF research is to improve the lives of all people affected by T1D by accelerating progress on the most promising opportunities for curing, better treating, and preventing T1D. JDRF collaborates with a wide spectrum of partners who share this goal. In addition to our research funding and leadership, JDRF’s outreach e orts provide practical support and resources for people with T1D and their families every step of the way as they live with T1D. JDRF is proud to partner with Children with Diabetes by sponsoring regional and national conferences as a charity partner, and supporting sessions at Friends for Life. For more information, visit the JDRF website at www.jdrf.org, or call 800-533-CURE.
Tandem Diabetes Care, Inc. is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. The t:slim X2 pump is capable of remote feature updates using a personal computer. Tandem is based in San Diego, California.
RX ONLY. The t:slim X2 insulin pump, Basal-IQ technology, and Control-IQ technology are intended for single patient use. The t:slim X2 pump, Basal-IQ technology, and Control-IQ technology are indicated for use with NovoLog or Humalog U-100 insulin.